
Relapsed or refractory primary mediastinal B-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-20082617

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised pembrolizumab for
patients with relapsed or refractory primary mediastinal B-cell
lymphoma. A patient’s treatment must not exceed a total of 35 cycles in
a lifetime.

Mediastinal B-cell lymphoma and listing dates

Mediastinal B-cell lymphoma is a cancer of the immune system.

Listing dates are:

-   pembrolizumab - 1 September 2020

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
